Can you answer the questions about this case ahead of joining Prof Sanyal's session by clicking here.
Ms. T, a 45-year-old woman with a BMI of 36 kg/m², has been recently diagnosed with metabolic-associated steatohepatitis (MASH) and type 2 diabetes. Despite taking metformin, she struggles with glycemic control. She's intrigued by the potential of GLP-1 receptor agonists but seeks more information on their effectiveness and how they might fit into her lifestyle.
Ms. T's busy schedule and frequent social engagements often involve dining out, making dietary changes challenging. She's motivated to improve her health but needs a sustainable approach that complements her lifestyle.
This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.
What are the long-term implications of GLP-1 receptor agonist therapy for patients like Ms. T, and how can we ensure continued adherence and optimal outcomes?
What are the long-term implications of GLP-1 receptor agonist therapy for patients like Ms. T, and how can we ensure continued adherence and optimal outcomes?
Are there any specific considerations or challenges in using GLP-1 receptor agonists in patients with both MASH and T2DM?
Are there any specific considerations or challenges in using GLP-1 receptor agonists in patients with both MASH and T2DM?
How can GLP-1 receptor agonists contribute to improved glycemic control and weight management in patients with T2DM, and how might this impact Ms. T's overall health?
How can GLP-1 receptor agonists contribute to improved glycemic control and weight management in patients with T2DM, and how might this impact Ms. T's overall health?
What does the latest evidence show about the efficacy of GLP-1 receptor agonists in improving liver health in patients with MASH, and how does this compare to other treatment options?
What does the latest evidence show about the efficacy of GLP-1 receptor agonists in improving liver health in patients with MASH, and how does this compare to other treatment options?